Latest Earnings Results: Q3 '26
Estimated EPS
-$1.78
Reported EPS
-$1.70
Surprise
+4.68%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Reported GAAP EPS of -$1.70 down -65.05% YoY
Bullish Takeaway
Palvella received FDA Priority Review and a February 28, 2027 action date for QTORIN rapamycin, reported SELVA improvements, and reported TOIVA efficacy results alongside plans for pivotal Phase 3 development.
Bearish Takeaway
Palvellas Q3 operating expenses and net loss were $22.7M and $24.6M; it has no product revenue, may need additional capital, and equity issuance may substantially dilute stockholders while relying on contract manufacturers.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$2.05 | -- | -- | N/A |
Q3 '26 | -$1.78 | -$1.70 | 4.68% | BEAT |
Q2 '26 | -$1.17 | -$1.52 | -29.55% | MISSED |
Q1 '26 | -$0.94 | -$1.20 | -28.34% | MISSED |
Q4 '25 | -$0.91 | -$1.08 | -18.53% | MISSED |